Neurodegenerative diseases
ELND005, an Aß aggregation inhibitor
The small molecule ELND005 is a beta amyloid anti-aggregation agent that also has been granted fast track designation by the FDA. In December 2007, Elan and Transition announced that the first patient had been dosed in a Phase 2 clinical study. This 18-month, randomized, double-blind, placebo-controlled, dose-ranging study is evaluating the safety and efficacy of ELND005 in patients with mild to moderate Alzheimer’s disease. In October 2008, Elan and Transition announced that the patient enrollment target for this study had been achieved with 353 patients enrolled. In December 2009, Elan and Transition announced that patients would be withdrawn from the two higher dose cohorts due to safety concerns. The study is continuing for the lower dose group.
ELND006 gamma secretase inhibitor
In November 2008, Elan announced that the development program for ELND006 had commenced with dosing in a Phase 1 clinical study, and other back-ups are in preclinical development.
LY450139 gamma secretase inhibitor
In addition to our internal program, Elan retains royalty and certain co-promotion rights to Eli Lilly & Company’s compound, LY450139, which arose from collaborative research between Elan and Lilly that began in 1988 and ended in 1998. In 2008, Lilly initiated Phase 3 trials for LY450139 for mild to moderate Alzheimer’s disease.
Alzheimer's Immunotherapy Program (Bapineuzumab, AAB002, ACC-001)
In September 2009, JANSSEN Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, acquired substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP), including bapineuzumab.
For information about AIP, including clinical trials, please contact:
JANSSEN Alzheimer Immunotherapy (Dublin)
Treasury Building
Lower Grand Canal Street
Dublin 2, Ireland
Telephone: +353.1.709.4900
Fax: +353.1.709.4950
JANSSEN Alzheimer Immunotherapy Research & Development, LLC (South San Francisco)
700 Gateway Blvd
South San Francisco, CA 94080
Telephone: +1 650.794.2500; +1 888.381.4595